Vincristine Sulfate Liposome Injection with Bendamustine and Rituximab as First-Line Therapy for B-Cell Lymphomas: A Phase I Study.
Thomas OllilaJames ButeraPamela EganJohn ReaganAnthony ThomasInna YakirevichKelsey MacKinnonJeannine MargolisJessica McMahonValerie RosatiAdam J OlszewskiPublished in: The oncologist (2022)
Vincristine sulfate liposomal injection at 2.25 mg/m2 can be safely combined with BR for indolent B-cell lymphoma, but given observed toxicities and recurrences, we did not pursue an expanded cohort.Clinical Trials Registration Number: ClinicalTrials.gov identifier NCT02257242.